Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 475

1.

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis.

Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Dodd S, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Jan 15. pii: jrheum.181194. doi: 10.3899/jrheum.181194. [Epub ahead of print]

PMID:
30647185
2.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Jan 15. pii: jrheum.181081. doi: 10.3899/jrheum.181081. [Epub ahead of print]

PMID:
30647174
3.

Communicating with the APHA.

Boers M.

Vet Rec. 2018 Dec 22;183(24):751. doi: 10.1136/vr.k5238. No abstract available.

PMID:
30573581
4.

Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people.

Palmowski A, Buttgereit T, Palmowski Y, Nielsen SM, Boers M, Christensen R, Buttgereit F.

Semin Arthritis Rheum. 2018 Nov 2. pii: S0049-0172(18)30487-6. doi: 10.1016/j.semarthrit.2018.10.017. [Epub ahead of print]

PMID:
30466715
5.

Effects of Co-medication with Glucocorticoids in Biologics Trials.

Boers M.

J Rheumatol. 2018 Nov;45(11):1605. doi: 10.3899/jrheum.180151. Epub 2018 Nov 1. No abstract available.

PMID:
30385699
6.

Validation of two PROMIS item banks for measuring social participation in the Dutch general population.

Terwee CB, Crins MHP, Boers M, de Vet HCW, Roorda LD.

Qual Life Res. 2019 Jan;28(1):211-220. doi: 10.1007/s11136-018-1995-0. Epub 2018 Sep 10.

PMID:
30203302
7.

Outcome measures for adherence data from a medication event monitoring system: A literature review.

Hartman L, Lems WF, Boers M.

J Clin Pharm Ther. 2019 Feb;44(1):1-5. doi: 10.1111/jcpt.12757. Epub 2018 Sep 1. Review.

PMID:
30171815
8.

Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review.

Chiarotto A, Maxwell LJ, Ostelo RW, Boers M, Tugwell P, Terwee CB.

J Pain. 2018 Aug 10. pii: S1526-5900(18)30400-0. doi: 10.1016/j.jpain.2018.07.009. [Epub ahead of print] Review.

PMID:
30099210
9.

Excessive Pricing Causes Poor Access to Biologics.

Boers M.

J Rheumatol. 2018 Jun;45(6):876. doi: 10.3899/jrheum.171401. No abstract available.

PMID:
29858458
10.

Evidence on the measurement properties of health-related quality of life instruments is largely missing in patients with low back pain: A systematic review.

Chiarotto A, Terwee CB, Kamper SJ, Boers M, Ostelo RW.

J Clin Epidemiol. 2018 Oct;102:23-37. doi: 10.1016/j.jclinepi.2018.05.006. Epub 2018 May 21. Review.

PMID:
29793009
11.

Evaluation of the wear-and-tear scale for therapeutic footwear, results of a generalizability study.

Dahmen R, Siemonsma PC, Monteiro S, Norman GR, Boers M, Lankhorst GJ, Roorda LD.

J Rehabil Med. 2018 Jun 15;50(6):569-574. doi: 10.2340/16501977-2339.

12.

Designing effective graphs to get your message across.

Boers M.

Ann Rheum Dis. 2018 Jun;77(6):833-839. doi: 10.1136/annrheumdis-2018-213396. Review.

PMID:
29748338
13.

A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials.

Boers M, Singh JA, Cofield SS, Bridges SL Jr, Moreland LW, O'Dell JR, Wu H, Leatherman S, Curtis JR.

Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23590. [Epub ahead of print]

PMID:
29691998
14.

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).

Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, Simpson E, Gerbens LAA, Boers M, Barbarot S, Stalder JF, Abuabara K, Aoki V, Ardeleanu M, Armstrong J, Bang B, Berents TL, Burton T, Butler L, Chubachi T, Cresswell-Melville A, DeLozier A, Eckert L, Eichenfield L, Flohr C, Futamura M, Gadkari A, Gjerde ES, van Halewijn KF, Hawkes C, Howells L, Howie L, Humphreys R, Ishii HA, Kataoka Y, Katayama I, Kouwenhoven W, Langan SM, Leshem YA, Merhand S, Mina-Osorio P, Murota H, Nakahara T, Nunes FP, Nygaard U, Nygårdas M, Ohya Y, Ono E, Rehbinder E, Rogers NK, Romeijn GLE, Schuttelaar MLA, Sears AV, Simpson MA, Singh JA, Srour J, Stuart B, Svensson Å, Talmo G, Talmo H, Teixeira HD, Thyssen JP, Todd G, Torchet F, Volke A, von Kobyletzki L, Weisshaar E, Wollenberg A, Zaniboni M.

Br J Dermatol. 2018 May;178(5):e332-e341. doi: 10.1111/bjd.16543. Epub 2018 Apr 19.

PMID:
29672835
15.

An unfavorable body composition is common in early arthritis patients: A case control study.

Turk SA, van Schaardenburg D, Boers M, de Boer S, Fokker C, Lems WF, Nurmohamed MT.

PLoS One. 2018 Mar 22;13(3):e0193377. doi: 10.1371/journal.pone.0193377. eCollection 2018.

16.

The controversy of using PGA to define remission in RA.

van Tuyl LHD, Boers M.

Nat Rev Rheumatol. 2018 Mar 21;14(4):245. doi: 10.1038/nrrheum.2018.36. No abstract available.

PMID:
29559715
17.

Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts.

Britsemmer K, van Schaardenburg D, Boers M, De Cock D, Verschueren P, Radner H, Smolen JS, van Tuyl LHD.

Clin Exp Rheumatol. 2018 May-Jun;36(3):362-370. Epub 2018 Feb 26.

PMID:
29533752
18.

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.

Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, Boers M.

Trials. 2018 Jan 25;19(1):67. doi: 10.1186/s13063-017-2396-3.

19.

Core outcome measurement instruments for clinical trials in nonspecific low back pain.

Chiarotto A, Boers M, Deyo RA, Buchbinder R, Corbin TP, Costa LOP, Foster NE, Grotle M, Koes BW, Kovacs FM, Lin CC, Maher CG, Pearson AM, Peul WC, Schoene ML, Turk DC, van Tulder MW, Terwee CB, Ostelo RW.

Pain. 2018 Mar;159(3):481-495. doi: 10.1097/j.pain.0000000000001117.

20.

A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain.

Chiarotto A, Ostelo RW, Boers M, Terwee CB.

J Clin Epidemiol. 2018 Mar;95:73-93. doi: 10.1016/j.jclinepi.2017.11.005. Epub 2017 Nov 14. Review.

PMID:
29154811
21.

More erronous statements about the use of frequentist statistical methods in medical research.

Boers M.

Clin Exp Rheumatol. 2017 Oct 26. [Epub ahead of print] No abstract available.

PMID:
29148414
22.

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

l'Ami MJ, Krieckaert CLM, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13. No abstract available.

PMID:
29133475
23.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

24.

Low-dose glucocorticoids in rheumatoid arthritis: blurring the line between therapeutic dose and substitution therapy?

Palmowski Y, Boers M, Buttgereit F.

Arthritis Care Res (Hoboken). 2017 Oct 26. doi: 10.1002/acr.23452. [Epub ahead of print]

25.

Graphics and statistics for cardiology: designing effective tables for presentation and publication.

Boers M.

Heart. 2018 Feb;104(3):192-200. doi: 10.1136/heartjnl-2017-311581. Epub 2017 Oct 13. Review.

PMID:
29030423
26.

Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.

Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, Hoekstra T.

Rheumatology (Oxford). 2018 Mar 1;57(3):555-562. doi: 10.1093/rheumatology/kex338. Review.

PMID:
29029294
27.

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.

PMID:
28939629
28.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
29.

Rheumatoid arthritis: Remission - keeping the patient experience front and centre.

van Tuyl LHD, Boers M.

Nat Rev Rheumatol. 2017 Oct;13(10):573-574. doi: 10.1038/nrrheum.2017.139. Epub 2017 Aug 31. No abstract available.

PMID:
28855692
30.

Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016.

Rasch LA, Boers M, Hill CL, Voshaar M, Hoogland W, de Wit M, Flurey C, Davis B, Hetland ML, Brahe CH, Gossec L, Wells GA, Tugwell P, Kuriya B, Goel N, Singh JA, Duarte C, Da Silva J, van Schaardenburg D, Proudman S, van Tuyl LHD; Working Group on the Patients’ Perspective on Remission in Rheumatoid Arthritis.

J Rheumatol. 2017 Dec;44(12):1889-1893. doi: 10.3899/jrheum.161111. Epub 2017 Aug 1.

PMID:
28765250
31.

Influence of timing of delayed hard palate closure on articulation skills in 3-year-old Danish children with unilateral cleft lip and palate.

Willadsen E, Boers M, Schöps A, Kisling-Møller M, Nielsen JB, Jørgensen LD, Andersen M, Bolund S, Andersen HS.

Int J Lang Commun Disord. 2018 Jan;53(1):130-143. doi: 10.1111/1460-6984.12331. Epub 2017 Jul 25.

PMID:
28741729
32.

Core outcome sets for research and clinical practice.

Chiarotto A, Ostelo RW, Turk DC, Buchbinder R, Boers M.

Braz J Phys Ther. 2017 Mar - Apr;21(2):77-84. doi: 10.1016/j.bjpt.2017.03.001. Epub 2017 Mar 18. Review.

33.

Observational studies on glucocorticoids are harmful!

Boers M.

Lupus Sci Med. 2017 Apr 7;4(1):e000219. doi: 10.1136/lupus-2017-000219. eCollection 2017. No abstract available.

34.

The Dutch-Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain.

Crins MHP, Terwee CB, Klausch T, Smits N, de Vet HCW, Westhovens R, Cella D, Cook KF, Revicki DA, van Leeuwen J, Boers M, Dekker J, Roorda LD.

J Clin Epidemiol. 2017 Jul;87:47-58. doi: 10.1016/j.jclinepi.2017.03.011. Epub 2017 Mar 28.

PMID:
28363734
35.

Validity of auditory perceptual assessment of velopharyngeal function and dysfunction - the VPC-Sum and the VPC-Rate.

Lohmander A, Hagberg E, Persson C, Willadsen E, Lundeborg I, Davies J, Havstam C, Boers M, Kisling-Møller M, Alaluusua S, Aukner R, Pedersen NH, Turunen L, Nyberg J.

Clin Linguist Phon. 2017;31(7-9):589-597. doi: 10.1080/02699206.2017.1302510. Epub 2017 Mar 31.

PMID:
28362219
36.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

37.

A Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 1. Planning and management.

Semb G, Enemark H, Friede H, Paulin G, Lilja J, Rautio J, Andersen M, Åbyholm F, Lohmander A, Shaw W, Mølsted K, Heliövaara A, Bolund S, Hukki J, Vindenes H, Davenport P, Arctander K, Larson O, Berggren A, Whitby D, Leonard A, Neovius E, Elander A, Willadsen E, Bannister RP, Bradbury E, Henningsson G, Persson C, Eyres P, Emborg B, Kisling-Møller M, Küseler A, Granhof Black B, Schöps A, Bau A, Boers M, Andersen HS, Jeppesen K, Marxen D, Paaso M, Hölttä E, Alaluusua S, Turunen L, Humerinta K, Elfving-Little U, Tørdal IB, Kjøll L, Aukner R, Hide Ø, Feragen KB, Rønning E, Skaare P, Brinck E, Semmingsen AM, Lindberg N, Bowden M, Davies J, Mooney J, Bellardie H, Schofield N, Nyberg J, Lundberg M, Karsten AL, Larson M, Holmefjord A, Reisæter S, Pedersen NH, Rasmussen T, Tindlund R, Sæle P, Blomhoff R, Jacobsen G, Havstam C, Rizell S, Enocson L, Hagberg C, Najar Chalien M, Paganini A, Lundeborg I, Marcusson A, Mjönes AB, Gustavsson A, Hayden C, McAleer E, Slevan E, Gregg T, Worthington H.

J Plast Surg Hand Surg. 2017 Feb;51(1):2-13. doi: 10.1080/2000656X.2016.1263202. Review.

PMID:
28218559
38.

Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 5. Speech outcomes in 5-year-olds - consonant proficiency and errors.

Willadsen E, Lohmander A, Persson C, Lundeborg I, Alaluusua S, Aukner R, Bau A, Boers M, Bowden M, Davies J, Emborg B, Havstam C, Hayden C, Henningsson G, Holmefjord A, Hölttä E, Kisling-Møller M, Kjøll L, Lundberg M, McAleer E, Nyberg J, Paaso M, Pedersen NH, Rasmussen T, Reisæter S, Andersen HS, Schöps A, Tørdal IB, Semb G.

J Plast Surg Hand Surg. 2017 Feb;51(1):38-51. doi: 10.1080/2000656X.2016.1254647. Review.

PMID:
28218556
39.

Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 4. Speech outcomes in 5-year-olds - velopharyngeal competency and hypernasality.

Lohmander A, Persson C, Willadsen E, Lundeborg I, Alaluusua S, Aukner R, Bau A, Boers M, Bowden M, Davies J, Emborg B, Havstam C, Hayden C, Henningsson G, Holmefjord A, Hölttä E, Kisling-Møller M, Kjøll L, Lundberg M, McAleer E, Nyberg J, Paaso M, Pedersen NH, Rasmussen T, Reisæter S, Søgaard Andersen H, Schöps A, Tørdal IB, Semb G.

J Plast Surg Hand Surg. 2017 Feb;51(1):27-37. doi: 10.1080/2000656X.2016.1254645.

PMID:
28218551
40.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
41.

"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements.

Palmowski Y, Buttgereit T, Dejaco C, Bijlsma JW, Matteson EL, Voshaar M, Boers M, Buttgereit F.

Arthritis Care Res (Hoboken). 2017 Aug;69(8):1134-1141. doi: 10.1002/acr.23185. Epub 2017 Jul 10. Review. Erratum in: Arthritis Care Res (Hoboken). 2018 Jan;70(1):144.

42.

Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.

Tarp S, Eric Furst D, Boers M, Luta G, Bliddal H, Tarp U, Heller Asmussen K, Brock B, Dossing A, Schjødt Jørgensen T, Thirstrup S, Christensen R.

Rheumatology (Oxford). 2017 Mar 1;56(3):417-425. doi: 10.1093/rheumatology/kew442. Review.

PMID:
28013201
43.

Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis.

Nikiphorou E, Mackie SL, Kirwan J, Boers M, Isaacs J, Morgan AW, Young A.

Rheumatology (Oxford). 2017 Apr 1;56(4):550-555. doi: 10.1093/rheumatology/kew416.

44.

Is it time to revisit the role of ultrasound in rheumatoid arthritis management?

D'Agostino MA, Boers M, Wakefield RJ, Emery P, Conaghan PG.

Ann Rheum Dis. 2017 Jan;76(1):7-8. doi: 10.1136/annrheumdis-2016-210453. Epub 2016 Nov 9.

45.

Response to: 'Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!' by Baker et al.

Boers M.

Ann Rheum Dis. 2017 Jun;76(6):e13. doi: 10.1136/annrheumdis-2016-210799. Epub 2016 Dec 1. No abstract available.

PMID:
27934679
46.

The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission.

van Tuyl LH, Sadlonova M, Hewlett S, Davis B, Flurey C, Goel N, Gossec L, Heegaard Brahe C, Hill CL, Hoogland W, Kirwan J, Hetland ML, van Schaardenburg D, Smolen JS, Stamm T, Voshaar M, Wells GA, Boers M.

Ann Rheum Dis. 2017 May;76(5):855-861. doi: 10.1136/annrheumdis-2016-209835. Epub 2016 Nov 30.

PMID:
27903508
47.

Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.

Tarp S, Furst DE, Dossing A, Østergaard M, Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor ME, Kristensen LE, Bliddal H, Christensen R.

Semin Arthritis Rheum. 2017 Jun;46(6):699-708. doi: 10.1016/j.semarthrit.2016.09.003. Epub 2016 Sep 14. Review.

PMID:
27769592
48.

Cross-Cultural and Construct Validity of the Animated Activity Questionnaire.

Peter WF, de Vet HCW, Boers M, Harlaar J, Roorda LD, Poolman RW, Scholtes VAB, Steultjens M, Hendry GJ, Roos EM, Guillemin F, Benedetti MG, Cavazzuti L, Escobar A, Dagfinrud H, Terwee CB.

Arthritis Care Res (Hoboken). 2017 Sep;69(9):1349-1359. doi: 10.1002/acr.23127. Epub 2017 Aug 13.

49.

Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.

Klokker L, Tugwell P, Furst DE, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Woodworth T, Leong AL, Goel N, Boers M, Brooks PM, Simon LS, Christensen R.

J Rheumatol. 2017 Dec;44(12):1916-1919. doi: 10.3899/jrheum.161105. Epub 2016 Oct 15.

PMID:
27744393
50.

Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT).

de Wit M, Kirwan JR, Tugwell P, Beaton D, Boers M, Brooks P, Collins S, Conaghan PG, D'Agostino MA, Hofstetter C, Hughes R, Leong A, Lyddiatt A, March L, May J, Montie P, Richards P, Simon LS, Singh JA, Strand V, Voshaar M, Bingham CO 3rd, Gossec L.

Patient. 2017 Apr;10(2):141-152. doi: 10.1007/s40271-016-0198-4.

Supplemental Content

Support Center